37 research outputs found
Clinical experience with ipilimumab 10 mg/kg in patients with melanoma treated at Italian centres as part of a European expanded access programme
Background: Patients with advanced melanoma are faced with a poor prognosis and, until recently, limited treatment options. Ipilimumab, a novel immunotherapy that blocks cytotoxic T-lymphocyte-associated antigen-4, was the first agent to improve survival of patients with advanced melanoma in a randomised, controlled phase 3 trial. We used data from an expanded access programme (EAP) at Italian centres to evaluate the clinical activity and safety profile of ipilimumab 10 mg/kg in patients with advanced melanoma in a setting more similar to that of daily practice. Methods. Data were collected from patients enrolled in an ipilimumab EAP across eight participating Italian centres. As per the EAP protocol, patients had life-threatening, unresectable stage III/IV melanoma, had failed or did not tolerate previous treatments and had no other therapeutic option available. Treatment comprised ipilimumab 10 mg/kg every 3 weeks for a total of four doses. If physicians believed patients would continue to derive benefit from ipilimumab treatment, maintenance therapy with ipilimumab 10 mg/kg was provided every 12 weeks. Tumour responses were assessed every 12 weeks using modified World Health Organization criteria and safety continuously monitored. Results: Seventy-four pretreated patients with advanced melanoma were treated with ipilimumab 10 mg/kg. Of these, 9 (13.0%) had an objective response, comprising 3 patients with a complete response and 6 with a partial response. Median overall survival was 7.0 months (95% confidence interval, 5.3-8.7) and 16.6% of patients were alive after 3 years. Forty-five patients (60.8%) reported treatment-related adverse events of any grade, which were most commonly low-grade pruritus, pain, fever and diarrhoea. Grade 3 or 4 treatment-related AEs were reported in 8 patients (10.8%). Conclusions: The clinical activity and safety profile of ipilimumab 10 mg/kg in the EAP was similar to that seen in previous clinical trials of ipilimumab in pretreated patient populations. © 2013 Altomonte et al.; licensee BioMed Central Ltd
Systematic evaluation of immune regulation and modulation
Cancer immunotherapies are showing promising clinical results in a variety of malignancies. Monitoring the immune as well as the tumor response following these therapies has led to significant advancements in the field. Moreover, the identification and assessment of both predictive and prognostic biomarkers has become a key component to advancing these therapies. Thus, it is critical to develop systematic approaches to monitor the immune response and to interpret the data obtained from these assays. In order to address these issues and make recommendations to the field, the Society for Immunotherapy of Cancer reconvened the Immune Biomarkers Task Force. As a part of this Task Force, Working Group 3 (WG3) consisting of multidisciplinary experts from industry, academia, and government focused on the systematic assessment of immune regulation and modulation. In this review, the tumor microenvironment, microbiome, bone marrow, and adoptively transferred T cells will be used as examples to discuss the type and timing of sample collection. In addition, potential types of measurements, assays, and analyses will be discussed for each sample. Specifically, these recommendations will focus on the unique collection and assay requirements for the analysis of various samples as well as the high-throughput assays to evaluate potential biomarkers
Unclassified renal cell carcinoma: an analysis of 85 cases.
OBJECTIVES: To compare cancer-specific mortality in patients with unclassified
renal cell carcinoma (URCC) vs clear cell RCC (CRCC) after nephrectomy, as URCC
is a rare but very aggressive histological subtype.
PATIENTS AND METHODS: Eighty-five patients with URCC and 4322 with CRCC were
identified within 6530 patients treated with either radical or partial
nephrectomy at 18 institutions. Of 85 patients with URCC, 55 were matched with
166 of 4322 for grade, tumour size, and Tumour, Node and Metastasis stages.
Kaplan-Meier and life-table analyses were used to address RCC-specific survival.
Subsequently, multivariate Cox regression analyses were used to test for
differences in RCC-specific survival in unmatched samples.
RESULTS: Of patients with URCC, 80% had Fuhrman grades III or IV, vs 37.8% for
CRCC. Moreover, 36.5% of patients with URCC had pathologically confirmed nodal
metastases, vs 8.6% with CRCC. Finally, 54.1% of patients with URCC had distant
metastases at the time of nephrectomy, vs 16.8% with CRCC. Despite these
differences in the overall analyses, after matching for tumour characteristics,
the URCC-specific mortality rate was 1.6 times higher (P = 0.04) in matched
analyses and 1.7 times higher (P = 0.001) in multivariate analyses.
CONCLUSIONS: These findings indicate that URCC presents with a higher stage and
grade, and even after controlling for the stage and grade differences,
predisposes patients to 1.6-1.7 times the mortality of CRCC